Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lupin Responds To FDA Warning Letter

US Agency Criticized Novel Laboratories Facility In New Jersey

Executive Summary

Lupin insists it has a “comprehensive remediation plan” to address deficiencies identified at its Novel Laboratories facility in New Jersey by an FDA warning letter. The Indian company says it does not anticipate any near-term commercial impact or supply disruptions linked to the letter.

You may also be interested in...



Lupin Appoints New Compliance Manager As More Deficiencies Found

Lupin has named a new head of compliance, emphasizing the importance of achieving the highest quality standards just weeks after the FDA notified the firm of observations following an inspection at its Indian facility in Tarapur.

Lupin Insists It Will Rebuild Quality Reputation Following Latest FDA Action

Lupin says it is rebuilding its reputation for quality and compliance after the US FDA awarded VAI status to a manufacturing facility in Goa that was hit by a warning letter back in 2017.

Lupin Partners With Biomm To Launch Pegfilgrastim Biosimilar In Brazil

Indian pharma firm Lupin has partnered with Biomm to market its proposed Neulasta biosimilar in Brazil, as it comes to the end of a tumultuous 2021.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151055

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel